8 ud af 8 tidsskrifter valgt, søgeord (pneumoni) valgt, emner højest 180 dage gamle, sorteret efter nyeste først.
15 emner vises.
1
Communicable disease threats report, 3-9 December 2023, week 49
ECDC
ECDC Communicable Disease Threats Report, 8.12.2023
Tilføjet 8.12.2023
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 3-9 December 2023 and includes updates on respiratory virus epidemiology in the EU/EEA, SARS-CoV-2 variant classification, measles, mpox, Mycoplasma pneumoniae, West Nile virus, and MERS-CoV.
Læs mere
2
Communicable disease threats report, 3-9 December 2023, week 49
ECDC
ECDC COVID-19 updates, 8.12.2023
Tilføjet 8.12.2023
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 3-9 December 2023 and includes updates on respiratory virus epidemiology in the EU/EEA, SARS-CoV-2 variant classification, measles, mpox, Mycoplasma pneumoniae, West Nile virus, and MERS-CoV.
Læs mere
3
How the New Outbreak in China Is Affecting the US and Other Regions
Medscape Infectious Diseases, 5.12.2023
Tilføjet 5.12.2023
A rise in respiratory illnesses in China and clusters of pneumonia in children and resistance to a common antibiotic have specialists taking a closer look at important trends. Medscape Medical News
Læs mere
4
Communicable disease threats report, 26 November - 2 December 2023, week 48
ECDC
ECDC Communicable Disease Threats Report, 2.12.2023
Tilføjet 2.12.2023
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 19 - 25 November 2023 and includes updates on human infection with influenza A(H1N2)v, influenza A(H5N1), an overview of respiratory virus epidemiology in the EU/EEA, respiratory infections due to Mycoplasma pneumoniae in the EU/EEA, HIV/AIDS surveillance 2023 (2022 data), West Nile virus, SARS-CoV-2 variant classification, and poliomyelitis.
Læs mere
5
Communicable disease threats report, 26 November - 2 December 2023, week 48
ECDC
ECDC COVID-19 updates, 1.12.2023
Tilføjet 1.12.2023
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 19 - 25 November 2023 and includes updates on human infection with influenza A(H1N2)v, influenza A(H5N1), an overview of respiratory virus epidemiology in the EU/EEA, respiratory infections due to Mycoplasma pneumoniae in the EU/EEA, HIV/AIDS surveillance 2023 (2022 data), West Nile virus, SARS-CoV-2 variant classification, and poliomyelitis.
Læs mere
6
Der er epidemi med mycoplasma-infektioner - også kendt som kold lungebetændelse
Statens Serum Institut, 29.11.2023
Tilføjet 29.11.2023
Der har siden sommeren været en stigning i antallet af luftvejsinfektioner med Mycoplasma pneumoniae, og forekomsten har nu nået et epidemisk niveau med væsentlig flere tilfælde end normalt.
Læs mere
7
Emergence and persistent spread of carbapenemase-producing Klebsiella pneumoniae high-risk clones in Greek hospitals, 2013 to 2022
Kyriaki Tryfinopoulou, Marius Linkevicius, Olga Pappa, Erik Alm, Kleon Karadimas, Olov Svartström, Michalis Polemis, Kassiani Mellou, Antonis Maragkos, Alma Brolund, Inga Fröding, Sophia David, Alkiviadis Vatopoulos, Daniel Palm, Dominique L Monnet, Theoklis Zaoutis, Anke Kohlenberg and Greek CCRE study group
Eurosurveillance latest updates, 24.11.2023
Tilføjet 24.11.2023
BackgroundPreliminary unpublished results of the survey of carbapenem- and/or colistin-resistant Enterobacterales (CCRE survey) showed the expansion of carbapenemase-producing Klebsiella pneumoniae (CPKP) sequence type (ST) 39 in 12 of 15 participating Greek hospitals in 2019. AimWe conducted a rapid survey to determine the extent of spread of CPKP high-risk clones in Greek hospitals in 2022 and compare the distribution of circulating CPKP clones in these hospitals since 2013. MethodsWe analysed whole genome sequences and epidemiological data of 310 K. pneumoniae isolates that were carbapenem-resistant or ‘susceptible, increased exposure’ from Greek hospitals that participated in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE, 2013–2014), in the CCRE survey (2019) and in a national follow-up survey (2022) including, for the latter, an estimation of transmission events. ResultsFive K. pneumoniae STs including ST258/512 (n = 101 isolates), ST11 (n = 93), ST39 (n = 56), ST147 (n = 21) and ST323 (n = 13) accounted for more than 90% of CPKP isolates in the dataset. While ST11, ST147 and ST258/512 have been detected in participating hospitals since 2013 and 2014, KPC-2-producing ST39 and ST323 emerged in 2019 and 2022, respectively. Based on the defined genetic relatedness cut-off, 44 within-hospital transmission events were identified in the 2022 survey dataset, with 12 of 15 participating hospitals having at least one within-hospital transmission event. ConclusionThe recent emergence and rapid spread of new high-risk K. pneumoniae clones in the Greek healthcare system related to within-hospital transmission is of concern and highlights the need for molecular surveillance and enhanced infection prevention and control measures.
Læs mere
8
Emergence and rapid dissemination of highly resistant NDM-14-producing Klebsiella pneumoniae ST147, France, 2022
Cécile Emeraud, Aba Mahamat, Agnès B. Jousset, Sandrine Bernabeu, Tania Goncalves, Camille Pommier, Delphine Girlich, Aurélien Birer, Christophe Rodriguez, Jean-Michel Pawlotsky, Thierry Naas, Rémy A. Bonnin and Laurent Dortet
Eurosurveillance latest updates, 20.10.2023
Tilføjet 20.10.2023
BackgroundSince 2021, an emergence of New Delhi metallo-β-lactamase (NDM)-14-producing Klebsiella pneumoniae has been identified in France. This variant with increased carbapenemase activity was not previously detected in Enterobacterales. AimWe investigated the rapid dissemination of NDM-14 producers among patients in hospitals in France. MethodsAll NDM-14-producing non-duplicate clinical isolates identified in France until June 2022 (n = 37) were analysed by whole genome sequencing. The phylogeny of NDM-14-producers among all K. pneumoniae sequence type (ST) 147 reported in France since 2014 (n = 431) was performed. Antimicrobial susceptibility testing, conjugation experiments, clonal relationship and molecular clock analysis were performed. ResultsThe 37 NDM-14 producers recovered in France until 2022 belonged to K. pneumoniae ST147. The dissemination of NDM-14-producing K. pneumoniae was linked to a single clone, likely imported from Morocco and responsible for several outbreaks in France. The gene blaNDM-14 was harboured on a 54 kilobase non-conjugative IncFIB plasmid that shared high homology with a known blaNDM-1-carrying plasmid. Using Bayesian analysis, we estimated that the NDM-14-producing K. pneumoniae ST147 clone appeared in 2020. The evolutionary rate of this clone was estimated to 5.61 single nucleotide polymorphisms per genome per year. The NDM-14 producers were highly resistant to all antimicrobials tested except to colistin, cefiderocol (minimum inhibitory concentration 2 mg/L) and the combination of aztreonam/avibactam. ConclusionHighly resistant NDM-14 producing K. pneumoniae can rapidly spread in healthcare settings. Surveillance and thorough investigations of hospital outbreaks are critical to evaluate and limit the dissemination of this clone.
Læs mere
9
Rapid spread of a novel NDM-producing clone of Klebsiella pneumoniae CC147, Northern Italy, February to August 2023
Irene Mileto, Greta Petazzoni, Marta Corbella, Stefano Gaiarsa, Cristina Merla, Angela Kuka, Marina Ramus, Cristina Terulla, Micaela Brandolini, Antonio Piralla, Patrizia Cambieri and Fausto Baldanti
Eurosurveillance latest updates, 20.10.2023
Tilføjet 20.10.2023
New Delhi metallo-beta-lactamase (NDM)-producing Klebsiella pneumoniae (Kp) ST147 caused a large multi-hospital outbreak in Italy from 2018 to 2021. We describe a new ST6668 NDM-producing Kp clone, belonging to CC147, which rapidly spread across hospitals in the Pavia province (Northern Italy) from February to August 2023. Genomic analyses revealed that ST6668 is different from ST147 and fast evolving. As shown here, genomic surveillance programmes are useful for tracking the spread of new clones with reduced susceptibility to most antibiotics.
Læs mere
10
Pneumonia, Not Just Inflammation, May Cause Severe COVID
Medscape Infectious Diseases, 26.09.2023
Tilføjet 26.09.2023
New research from Northwestern University and the University of Wisconsin, however, is pointing to bacterial pneumonia as the cause of many severe COVID deaths. WebMD Health News
Læs mere
11
Worm Pulled From Woman's Brain in Case That 'Stunned'
Medscape Infectious Diseases, 22.09.2023
Tilføjet 22.09.2023
A 64-year-old woman diagnosed with pneumonia had abdominal pain, diarrhea, dry cough, and night sweats. A year of inexplicable symptoms ended in an open biopsy and a live, stringlike worm. Medscape Medical News
Læs mere
12
Three Cases of Community-Acquired Pneumonia
Medscape Infectious Diseases, 19.09.2023
Tilføjet 19.09.2023
Clinicians should consider all three etiologies on community-acquired pneumonia presentation to improve antimicrobial stewardship and patient outcomes. CDC Expert Commentary
Læs mere
13
Sustained increase of paediatric invasive Streptococcus pyogenes infections dominated by M1UK and diverse emm12 isolates, Portugal, September 2022 to May 2023
Catarina Gouveia, Maria Paula Bajanca-Lavado, Rafael Mamede, Ana Araújo Carvalho, Fernanda Rodrigues, José Melo-Cristino, Mario Ramirez, Ana Friães, Portuguese Group for the Study of Streptococcal Infections and Portuguese Study Group of Pediatric Invasive Streptococcal Disease
Eurosurveillance latest updates, 8.09.2023
Tilføjet 8.09.2023
Since autumn 2022, observed numbers of paediatric invasive group A Streptococcus infections in Portugal (n = 89) were higher than in pre-COVID-19 seasons. Between September 2022 and May 2023, the dominant diagnoses were pneumonia (25/79), mostly with empyema (20/25), and sepsis (22/79). A number of cases required admission to intensive care (27/79) and surgery (35/79), and the case fatality rate was 5.1% (4/79). Genomic sequencing (n = 55) revealed multiple genetic lineages, dominated by the M1UK sublineage (26/55) and more diverse emm12 isolates (12/55).
Læs mere
14
A Q fever outbreak among visitors to a natural cave, Bizkaia, Spain, December 2020 to October 2021
Ana Hurtado, Ion I Zendoia, Eva Alonso, Xabier Beraza, Joseba Bidaurrazaga, Blanca Ocabo, Iñaki Arrazola, Aitor Cevidanes, Jesús F Barandika and Ana L García-Pérez
Eurosurveillance latest updates, 14.07.2023
Tilføjet 14.07.2023
We describe a large Q fever outbreak reported in Spain, including 108 cases, 53 with pneumonia and 27 requiring hospitalisations. The first cases were detected in February 2021 among rock climbers visiting a cave in Bizkaia, and the last case was detected in October 2021. Most cases were notified after the Easter holiday (April–May 2021). More males (63.9%) than females (36.1%) were infected (median ages: 42 (1–68) and 39 years (6–61), respectively). We detected Coxiella burnetii by PCR in faecal, dust and/or aerosol samples taken inside the cave in March 2021, and in dust and aerosol samples collected between March 2021 and February 2023. Coxiella burnetii from dust samples were cultured on Vero cells, showing viability for 24 months. Based on serological and genotyping data, goats sheltering in the cave were the most likely source of infection. The cave was closed on 29 April 2021, movements of goats and sheep in the area were restricted (March–July 2021), and the animals were vaccinated in October 2021. Investigation of Q fever outbreaks requires a multidisciplinary One Health approach as these outbreaks can occur in unexpected places like natural sites where animals are present.
Læs mere
15
Nationwide, population-based observational study of the molecular epidemiology and temporal trend of carbapenemase-producing Enterobacterales in Norway, 2015 to 2021
Oskar Ljungquist, Bjørg Haldorsen, Anna Kaarina Pöntinen, Jessin Janice, Ellen Haldis Josefsen, Petter Elstrøm, Oliver Kacelnik, The Norwegian Study Group on CPE, Arnfinn Sundsfjord and Ørjan Samuelsen
Eurosurveillance latest updates, 7.07.2023
Tilføjet 7.07.2023
IntroductionNational and regional carbapenemase-producing Enterobacterales (CPE) surveillance is essential to understand the burden of antimicrobial resistance, elucidate outbreaks, and develop infection-control or antimicrobial-treatment recommendations. AimThis study aimed to describe CPE and their epidemiology in Norway from 2015 to 2021. MethodsA nationwide, population-based observational study of all verified clinical and carriage CPE isolates submitted to the national reference laboratory was conducted. Isolates were characterised by antimicrobial susceptibility testing, whole genome sequencing (WGS) and basic metadata. Annual CPE incidences were also estimated. ResultsA total of 389 CPE isolates were identified from 332 patients of 63 years median age (range: 0–98). These corresponded to 341 cases, 184 (54%) being male. Between 2015 and 2021, the annual incidence of CPE cases increased from 0.6 to 1.1 per 100,000 person-years. For CPE-isolates with available data on colonisation/infection, 58% (226/389) were associated with colonisation and 38% (149/389) with clinical infections. WGS revealed a predominance of OXA-48-like (51%; 198/389) and NDM (34%; 134/389) carbapenemases in a diversified population of Escherichia coli and Klebsiella pneumoniae, including high-risk clones also detected globally. Most CPE isolates were travel-related (63%; 245/389). Although local outbreaks and healthcare-associated transmission occurred, no interregional spread was detected. Nevertheless, 18% (70/389) of isolates not directly related to import points towards potentially unidentified transmission routes. A decline in travel-associated cases was observed during the COVID-19 pandemic. ConclusionsThe close-to-doubling of CPE case incidence between 2015 and 2021 was associated with foreign travel and genomic diversity. To limit further transmission and outbreaks, continued screening and monitoring is essential.
Læs mere